AbbVie Inc. – Product Pipeline Review

Global Markets Direct’s, ‘AbbVie Inc. – Product Pipeline Review – 2016’, provides an overview of the AbbVie Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by AbbVie Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of AbbVie Inc.

The report provides overview of AbbVie Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses AbbVie Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features AbbVie Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate AbbVie Inc.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for AbbVie Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding AbbVie Inc.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

AbbVie Inc. Snapshot 6

AbbVie Inc. Overview 6

Key Information 6

Key Facts 6

AbbVie Inc. - Research and Development Overview 7

Key Therapeutic Areas 7

AbbVie Inc. - Pipeline Review 14

Pipeline Products by Stage of Development 14

Pipeline Products - Monotherapy 15

Pipeline Products - Combination Treatment Modalities 16

Pipeline Products - Partnered Products 17

Pipeline Products - Out-Licensed Products 20

AbbVie Inc. - Pipeline Products Glance 22

AbbVie Inc. - Late Stage Pipeline Products 22

AbbVie Inc. - Clinical Stage Pipeline Products 25

AbbVie Inc. - Early Stage Pipeline Products 27

AbbVie Inc. - Drug Profiles 30

adalimumab 30

daclizumab 33

elotuzumab 37

ibrutinib 39

venetoclax 46

Viekira-3QD 50

(ombitasvir + paritaprevir + ritonavir) + dasabuvir 51

atrasentan hydrochloride 52

elagolix sodium 54

fluvoxamine maleate 56

glecaprevir 57

glecaprevir + pibrentasvir 59

ombitasvir 61

paricalcitol 63

paritaprevir 64

pibrentasvir 66

upadacitinib tartrate 67

veliparib 68

depatuxizumab mafodotin 72

ABT-122 74

ABT-436 76

ABT-981 77

depatuxizumab 78

navitoclax dihydrochloride 79

ABBV-075 81

ABBV-084 82

ABBV-085 83

ABBV-221 84

ABBV-672 85

ABBV-838 86

ABBV-8E12 87

ABT-165 88

ABT-257 89

ABT-399 90

ABT-555 91

ABT-700 92

ABT-767 93

ABT-957 94

ilorasertib 95

A-1048400 97

A-1262543 98

A-1264087 99

A-431404 100

A-705253 101

A-889425 102

A-988315 103

ABT-207 104

ABT-737 105

APG-880 107

Biologics for Undisclosed Indication 108

h-5F9AM8 109

Monoclonal Antibodies to Inhibit RGMa for Multiple Sclerosis 110

Monoclonal Antibody Conjugates for Oncology 111

Small Molecule to Inhibit PKC Theta for Autoimmune Disease 112

Small Molecule to Inhibit WEE-1 for Oncology 113

Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Uterine Fibroids and Oncology 114

SOL-1 115

A-893 116

Monoclonal Antibodies for Chronic Pain 117

Small Molecules to Inhibit CDPK1 for Protozoal Infections 118

Small Molecules to Inhibit Jak1 for Undisclosed Indication 119

Small Molecules to Inhibit MCL-1 for Cancer 120

AbbVie Inc. - Pipeline Analysis 121

AbbVie Inc. - Pipeline Products by Target 121

AbbVie Inc. - Pipeline Products by Route of Administration 125

AbbVie Inc. - Pipeline Products by Molecule Type 126

AbbVie Inc. - Pipeline Products by Mechanism of Action 127

AbbVie Inc. - Recent Pipeline Updates 130

AbbVie Inc. - Dormant Projects 177

AbbVie Inc. - Discontinued Pipeline Products 182

Discontinued Pipeline Product Profiles 182

AbbVie Inc. - Company Statement 187

AbbVie Inc. - Locations And Subsidiaries 190

Head Office 190

Other Locations & Subsidiaries 190

Appendix 198

Methodology 198

Coverage 198

Secondary Research 198

Primary Research 198

Expert Panel Validation 198

Contact Us 198

Disclaimer 199

List of Tables

List of Tables

AbbVie Inc., Key Information 11

AbbVie Inc., Key Facts 11

AbbVie Inc. – Pipeline by Indication, 2016 13

AbbVie Inc. – Pipeline by Stage of Development, 2016 19

AbbVie Inc. – Monotherapy Products in Pipeline, 2016 20

AbbVie Inc. – Combination Treatment Modalities in Pipeline, 2016 21

AbbVie Inc. – Partnered Products in Pipeline, 2016 22

AbbVie Inc. – Partnered Products/ Combination Treatment Modalities, 2016 23

AbbVie Inc. – Out-Licensed Products in Pipeline, 2016 25

AbbVie Inc. – Out-Licensed Products/ Combination Treatment Modalities, 2016 26

AbbVie Inc. – Pre-Registration, 2016 27

AbbVie Inc. – Filing rejected/Withdrawn, 2016 28

AbbVie Inc. – Phase III, 2016 29

AbbVie Inc. – Phase II, 2016 30

AbbVie Inc. – Phase I, 2016 31

AbbVie Inc. – Preclinical, 2016 32

AbbVie Inc. – Discovery, 2016 34

AbbVie Inc. – Pipeline by Target, 2016 126

AbbVie Inc. – Pipeline by Route of Administration, 2016 130

AbbVie Inc. – Pipeline by Molecule Type, 2016 131

AbbVie Inc. – Pipeline Products by Mechanism of Action, 2016 132

AbbVie Inc. – Recent Pipeline Updates, 2016 135

AbbVie Inc. – Dormant Developmental Projects,2016 182

AbbVie Inc. – Discontinued Pipeline Products, 2016 187

AbbVie Inc., Subsidiaries 195

List of Figures

List of Figures

AbbVie Inc. – Pipeline by Top 10 Indication, 2016 13

AbbVie Inc. – Pipeline by Stage of Development, 2016 19

AbbVie Inc. – Monotherapy Products in Pipeline, 2016 20

AbbVie Inc. – Partnered Products in Pipeline, 2016 22

AbbVie Inc. – Pipeline by Top 10 Target, 2016 126

AbbVie Inc. – Pipeline by Route of Administration, 2016 130

AbbVie Inc. – Pipeline by Molecule Type, 2016 131

AbbVie Inc. – Pipeline Products by Top 10 Mechanism of Action, 2016 132

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports